Compare · DXCM vs NYXH
DXCM vs NYXH
Side-by-side comparison of DexCom Inc. (DXCM) and Nyxoah SA (NYXH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and NYXH operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $29.58B, about 365.5x NYXH ($80.9M).
- DXCM has been more active in the news (15 items in the past 4 weeks vs 5 for NYXH).
- DXCM has more recent analyst coverage (25 ratings vs 9 for NYXH).
- Company
- DexCom Inc.
- Nyxoah SA
- Price
- -
- -
- Market cap
- $29.58B
- $80.9M
- 1M return
- +1.33%
- -
- 1Y return
- +31.81%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2021
- News (4w)
- 15
- 5
- Recent ratings
- 25
- 9
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Nyxoah SA
Nyxoah S.A., a health-technology company, focuses on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. It offers Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treast moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is based in Mont-Saint-Guibert, Belgium.
Latest DXCM
- Dexcom Marks Athenry Opening With Celebration of Commercial Production Milestone
- EVP Chief Legal Compliance Off Michael Jon Brown sold $141,882 worth of shares (1,700 units at $83.46) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 95,034 units (SEC Form 4)
- EVP Chief Legal Compliance Off Brown Michael Jon covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 1% to 96,734 units (SEC Form 4) to cover withholding tax
- EVP, COO & CFO Sylvain Jereme M covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 0.99% to 145,377 units (SEC Form 4) (for tax liability)
- EVP Chief People & Culture Off Stern Sadie covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 1% to 119,462 units (SEC Form 4) to satisfy withholding obligation
- President, CEO, and Director Leach Jacob Steven covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 0.35% to 417,457 units (SEC Form 4) to satisfy withholding tax
- Dexcom Announces Upcoming Conference Presentation
- SEC Form SCHEDULE 13G filed by DexCom Inc.
- Director Ashley Euan A. gifted 2,389 shares (SEC Form 4)
- Dexcom Invites the Global Diabetes Community to Share Their Stories Through A Letter to Diabetes Campaign
Latest NYXH
- SEC Form 6-K filed by Nyxoah SA
- Nyxoah Obtains Default Decision Against Inspire Medical Systems in Unified Patent Court Case
- SEC Form 6-K filed by Nyxoah SA
- Nyxoah Reports Third Quarter 2026 Financial and Operating Results
- Nyxoah to Release Third Quarter 2026 Financial Results on November 5, 2026
- SEC Form 6-K filed by Nyxoah SA
- Nyxoah Announces Preliminary Results for the Third Quarter of 2026 and Adjusts Revenue Guidance for 2026
- Full 12-Month Data from the ACCCESS U.S. Pivotal Study in Complete Concentric Collapse Patients Presented at ISSS 2026
- SEC Form 6-K filed by Nyxoah SA
- Nyxoah Appoints Liam Kelly as Chief Executive Officer